Scientists from the Sheffield Institute for Translational Neuroscience (SITraN) recently begun ground breaking research to develop a gene therapy for the devastating neurological disease ALS.
Professor Mimoun Azzouz, leading Gene Therapy Scientist and Chair of Translational Neuroscience, said: “This pioneering project has the potential to deliver the first meaningful neuroprotective therapy for MND, offering a real beacon of hope for patients and their families living with this cruel disease.
Silencing the SOD1 gene
“Silencing the SOD1 gene that is associated with 20 per cent of familial MND cases may be as close as we can get to a cure for MND in the near future. Our ultimate goal is to get the gene therapy for SOD1-related MND into the clinic as soon as possible. Gene therapy is regarded as an innovative technique with huge potential for the treatment of neurological conditions including motor neurone disease.”
We plan to use the gene therapy initially in an inherited form of MND caused by alterations in a gene known as SOD1, but we intend to broaden the approach to other groups of MND patients in the future. ALS/MND is characterised by the progressive loss of nerve cells (motor-neurons) that connect the brain with the muscles to control movements. As the disease progresses, patients may lose the ability to walk, move, eat, talk and finally breathe.
This pioneering research, funded by a £2.2 million donation from an anonymous donor, is jointly led by gene therapy expert Professor Mimoun Azzouz and world-leading MND expert Professor Dame Pam Shaw – the founder of SITraN.
“MND is considered a rare disease and therefore tends to be overlooked in terms of funding for the development of new therapies. This emphasises the importance of the extremely generous donation made by a philanthropist based in the USA, for our gene therapy research programme and for our patients with MND who don’t have time to wait. ” said Professor Shaw.
“The experience that we have accumulated with our gene therapy and Clinical Trials programmes at SITraN is crucial to develop this new therapy for patients with ALS/MND. We plan submission for regulatory approval by August 2015, for permission to take this therapy to patients in the clinic. ”
Researchers at SITraN will now start a large preclinical study before the first-in-human clinical trial. The team is also currently preparing for the first ever UK gene therapy trial in humans for Spinal Muscular Atrophy (SMA) which is a childhood form of MND.